This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Prediction of Response to Anti-PD-1 Therapy in Patients With Non-small-cell Lung Cancer by Electronic Nose Analysis of Exhaled Breath
Immune checkpoint inhibitors have revolutionized treatment of non-small cell lung cancer. In this study, breath prophiles were collected from 143 patients and a single biomarker profile was created that detected responses to anti-PD-1 treatment with 89% accuracy.